This effect was achieved by an increased CD8+ to CD4+CD25+ T-cell ratio, whereas it failed in athymic human lung cancer xenograft models, suggesting the requirement of mature T-cells to exert RXR-mediated inhibition of the oncogenic HER2-MAPK cascade. The gene discussed is ERBB2; the disease is lung carcinoma.